Biogen Stocks Fall As They Tweak Their Research
The Biotechnology company Biogen is changing plans for their study on Alzheimer’s based on mid-study findings, making investors less confident. Based on their findings, 510 patients will need to be added to the final stage of the study. Biogen CMO Al Sandrock said, “ We did do a preplanned blinded sample size re-estimation. We did see more variability in the primary endpoint than assumed when we did the original sample size estimation, so we decided to increase the sample size to maintain 90% power. Therefore, we’re going to add 510 patients to the two studies.” With the recent changes and growing concerns for their stockholders, hopefully Biogens study will still pay off.
Follow us on social media for the latest updates in B2B!